Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;15(2):2177-2181.
doi: 10.3892/etm.2017.5639. Epub 2017 Dec 15.

The role of Dexamethasone in clinical pharmaceutical treatment for patients with cataract surgery

Gaokun Zhang  1 , Shuang Liu  2 , Lieying Yang  3 , Yanqing Li  3
Affiliations

The role of Dexamethasone in clinical pharmaceutical treatment for patients with cataract surgery

Gaokun Zhang et al. Exp Ther Med. 2018 Feb.

Abstract

The aim of the present study is to determine the efficacy of dexamethasone (DEX) vs. indomethacin (IND) and ciprofloxacin (CIP) in modulating immediate inflammation following cataract surgery. A total of 644 patients with cataract were recruited and inflammation was investigated during the perioperative period. The management protocol was similar in both groups. Each drug was given four times a day for 30 days starting 7 days prior to surgery. The primary efficacy criteria for evaluation were the reduction in anterior chamber (AC) flare and AC inflammation score, in addition, a different secondary efficacy and safety evaluation criteria were maintained. The results demonstrated that the average inflammation score was 1.2±0.8 in the DEX group, which was significantly lower compared with the IND (1.9±0.7) and CIP (1.8±0.6) groups. Intra-ocular pressure was decreased following treatment with DEX, while intra-ocular pressure was slightly increased in the IND (1.9±0.7) and CIP (1.8±0.6) groups. The final visual outcomes for patients postcataract surgery were clinically superior in the DEX group compared with that of the IND and CIP groups (P=0.034 and P=0.042, respectively), but there was no significant difference between the ND and CIP groups (P=0.78). Outcomes indicated that AC inflammation, conjunctival hyperaemia, corneal and lid oedema, ocular infection, pain, photophobia, and tearing were significantly improved in each group. No significant poor local tolerance or adverse reaction was observed in the DEX, IND and CIP groups. In conclusion, the outcomes of the present study suggest that DEX serves an important role in the clinical pharmaceutical treatment of patients with cataract surgery.

Keywords: anterior chamber inflammation; cataract; clinical pharmaceutical treatment; dexamethasone.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The effective phacoemulsification times for patients with cataract in DEX, IND and CIP groups. DEX, dexamethasone; IND, indomethacin; CIP, ciprofloxacin.
Figure 2.
Figure 2.
Average AC inflammation score for patients with cataract in DEX, IND and CIP groups prior and post phacoemulsification surgery. DEX, dexamethasone; IND, indomethacin; CIP, ciprofloxacin. **P<0.01.
Figure 3.
Figure 3.
DEX, IND and CIP significantly improves aqueous for patients after phacoemulsification surgery. DEX, dexamethasone; IND, indomethacin; CIP, ciprofloxacin. **P<0.01.
Figure 4.
Figure 4.
DEX, IND and CIP significantly decreases intra-ocular pressure for patients after phacoemulsification surgery. DEX, dexamethasone; IND, indomethacin; CIP, ciprofloxacin. *P<0.05, **P<0.01.
Figure 5.
Figure 5.
DEX significantly improves final visual outcomes compared to IND and CIP groups. DEX, dexamethasone; IND, indomethacin; CIP, ciprofloxacin.*P<0.05, **P<0.01.
Figure 6.
Figure 6.
DEX significantly meliorated retinoschisis compared to IND and CIP groups. DEX, dexamethasone; IND, indomethacin; CIP, ciprofloxacin. **P<0.01.
Figure 7.
Figure 7.
DEX, IND and CIP is safe agent for patients after phacoemulsification surgery. DEX, dexamethasone; IND, indomethacin; CIP, ciprofloxacin.
See this image and copyright information in PMC

References

    1. Bilge AH, Aykan U, Akin T, Unsal U. Review of sterile, postoperative, anterior segment inflammation following cataract extraction and intraocular lens implantation. Eur J Ophthalmol. 2005;15:224–227. - PubMed
    1. Benemei S, Nicoletti P, Geppetti P, Bonciani M. Cataract in chronic cluster headache: Two case reports and review of the literature. J Headache Pain. 2008;9:401–403. doi: 10.1007/s10194-008-0066-2. - DOI - PMC - PubMed
    1. Drolsum L, Ringvold A, Nicolaissen B. Cataract and glaucoma surgery in pseudoexfoliation syndrome: A review. Acta Ophthalmol Scand. 2007;85:810–821. doi: 10.1111/j.1600-0420.2007.00903.x. - DOI - PubMed
    1. Subzwari S, Desapriya E, Scime G, Babul S, Jivani K, Pike I. Effectiveness of cataract surgery in reducing driving-related difficulties: A systematic review and meta-analysis. Inj Prev. 2008;14:324–328. doi: 10.1136/ip.2007.017830. - DOI - PubMed
    1. Laurell CG, Zetterström C. Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery. Br J Ophthalmol. 2002;86:1380–1384. doi: 10.1136/bjo.86.12.1380. - DOI - PMC - PubMed